Analytical Data
-
Gene name
PVRL4
- Application
-
Alternative Names
PVRL4；LNIR；Nectin-4
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q96NY8
-
Expression Region
32-349aa
-
AA Sequence
GELETSDVVTVVLGQDAKLPCFYRGDSGEQVGQVAWARVDAGEGAQELAL LHSKYGLHVSPAYEGRVEQPPPPRNPLDGSVLLRNAVQADEGEYECRVST FPAGSFQARLRLRVLVPPLPSLNPGPALEEGQGLTLAASCTAEGSPAPSV TWDTEVKGTTSSRSFKHSRSAAVTSEFHLVPSRSMNGQPLTCVVSHPGLL QDQRITHILHVSFLAEASVRGLEDQNLWHIGREGAMLKCLSEGQPPPSYN WTRLDGPLPSGVRVDGDTLGFPPLTTEHSGIYVCHVSNEFSSRDSQVTVD VLDPQEDSGKQVDLVSAS
-
Molecular Weight
36 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
PVRL4, also known as Poliovirus Receptor-Like 4, is a member of the immunoglobulin superfamily that has gained significant attention in recent years due to its potential roles in various physiological and pathological processes, particularly in cancer biology. Research indicates that PVRL4 can influence tumor progression and immune evasion, making it a potential target for therapeutic interventions. Expression of PVRL4 has been reported in various human tissues, and its upregulation has been associated with poor prognosis in several types of cancers, including breast and lung cancer. Furthermore, PVRL4 interacts with cell adhesion molecules, which suggests its involvement in cellular signaling pathways that govern cancer cell behavior. Understanding the mechanisms by which PVRL4 contributes to tumorigenesis may provide insights into novel strategies for cancer therapy, as well as improve the efficacy of existing treatments. Given its prominence in immune modulation and oncogenesis, research into PVRL4-recombinant proteins is crucial for elucidating its function and exploring its potential as a biomarker or therapeutic target in oncology. This highlights the need for comprehensive studies, including structural analysis and functional assays, to fully characterize PVRL4's characteristics and interactions at the molecular level, ultimately leading to advancements in targeted cancer therapies.
